Clinical Trial Update: Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) [Phase 1, Phase 2]

View source ↗

Summary

Early-phase trial evaluating safety, efficacy, pharmacokinetics, and pharmacodynamics of avelumab in combination with crizotinib or PF-06463922 in non-small cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avelumab (avelumab)
• Crizotinib (crizotinib)
• PF-06463922

Snippet

Sponsor: Pfizer | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-02-09